title: Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.
abstract: BACKGROUND
  Cognitive deficits are recognized as a critical determinant of functional outcomes in schizophrenia; and second generation antipsychotic drugs have been touted for their potential to enhance cognitive functioning and community tenure.
  
  
  OBJECTIVE
  The study examined the relative merits of olanzapine and quetiapine in improving cognitive deficits and enhancing psychosocial functioning in a sample of community dwelling adults previously treated with first generation antipsychotic drugs for schizophrenia.
  
  
  METHODS
  In a prospective, rater-blinded study, 86 participants were randomized to receive either olanzapine or quetiapine, and assessed at baseline and after 3, 6, 9 and 12 months. Outcome measures included, besides symptoms and side effects rating scales, the subjective scale to investigate cognition in schizophrenia (SSTICS), a computer-assisted cognitive test battery (COGLAB), the sickness impact profile (SIP), the global assessment of functioning (GAF) scale, and the drug attitude inventory (DAI).
  
  
  RESULTS
  Both olanzapine and quetiapine were equally effective in improving symptom severity and decreasing the neurological side effects. Quetiapine was significantly better tolerated (p=0.002), improved self-rated cognitive dysfunction (p=0.002) and subjects' performance on selected neurocognitive tasks (p=0.01). Olanzapine use was associated with greater symptom stability, fewer drop outs (p=0.01) and frequent metabolic aberrations (p=0.001). The accrued benefits of drug therapy, however, were not reflected as significant gains in daily functioning and quality of life.
  
  
  CONCLUSIONS
  Quetiapine is noted to have specific cognition enhancing properties in schizophrenia that warrants further exploration. The observed clinical and cognitive benefits associated with quetiapine may likely be attributable to its loose binding to, and fast dissociation from the dopamine receptors. Olanzapine has proved to be a reliable antipsychotic drug with a greater liability to cause metabolic abnormalities.
authors.affiliation: McMaster University, Canada. vorugl@mcmaster.ca
authors.forename: L P
authors.initials: LP
authors.lastname: Voruganti
authors.forename: A G
authors.initials: AG
authors.lastname: Awad
authors.forename: G
authors.initials: G
authors.lastname: Parker
authors.forename: C
authors.initials: C
authors.lastname: Forrest
authors.forename: Y
authors.initials: Y
authors.lastname: Usmani
authors.forename: M L D
authors.initials: ML
authors.lastname: Fernando
authors.forename: S
authors.initials: S
authors.lastname: Senthilal
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001364:Awareness; D001569:Benzodiazepines / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects*; D003987:Dibenzothiazepines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D011446:Prospective Studies; D011788:Quality of Life; D000069348:Quetiapine Fumarate; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D012565:Schizophrenic Psychology; D016037:Single-Blind Method; D013028:Space Perception; D016896:Treatment Outcome; D014796:Visual Perception
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D000077152:Olanzapine